In recommending Kimmtrak, NICE factored in a new commercial agreement with the sponsor and changed its 2023 negative opinion.

Novartis licensed PTC's PTC518 Huntington's disease program and related molecules and will pay $1 billion upfront as well as other costs.

In the study, the firm will enroll previously treated patients whose tumors are positive for FRα based on IHC testing.

A neurologist orders the wrong genetic test for a patient experiencing peripheral neuropathy and doesn't realize it even upon ...

The firm plans to put the proceeds toward further developing its cell therapy in CD33- or FLT3-expressing AML and for other R&D activities.

The trials are evaluating an individualized neoantigen vaccine with Keytruda as an adjuvant therapy for non-small cell lung cancer.

The agency is also evaluating if there's a need for further regulatory action based on reports of hematologic malignancies from clinical trials of the therapy.

As the popularity of drugs like Ozempic and Mounjaro soar, researchers, doctors, biotechs, and diagnostic firms see a role ...

The global Phase III VANCE trial of the autologous EBV-targeted T-cell therapy was the largest trial of a solid tumor cell ...

The Missouri hospital system designed its own 13-gene PGx panel, which it runs at its molecular genetics lab and calls the ...

In a first-of-its-kind trial, physicians will review neurofilament test results with patients and decide whether to continue ...

The addition of tiragolumab to Tecentriq in patients with advanced PD-L1-high NSCLC failed to improve overall survival in a Phase III trial.